BenzingaOctober 19, 2026 at 12:05 AM NY8 Days Ago
AbbVie’s Dual-Target Drug Shows Phase 2 Results for Hard-to-Treat Crohn’s Disease
AbbVie (NYSE:ABBV) today announced that its investigational ABBV-466, a novel dual-targeting therapy against IL-23 p19 and integrin α4β7, demonstrated higher rates of endoscopic remissiona at Week 12 than either
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga
